Medpace offers a full-service model encompassing all phases of clinical trials (Phase I-IV), providing services such as:
Study Start-up and Clinical Trial Management
Clinical Monitoring and Data Management
Medical Affairs and Clinical Safety
Regulatory Affairs and Medical Writing
Quality Assurance and Technology Integration
Additionally, Medpace operates its own central laboratories, bioanalytical labs, imaging core labs, ECG core labs, and a Phase I unit, ensuring integrated and efficient execution of clinical trials. Medpace Corporate
Medpace's therapeutic focus includes:
Cardiovascular
Dermatology
Endocrine & Metabolic
Gastroenterology & Hepatology
Hematology & Oncology
Immunology & Inflammation
Infectious Diseases & Vaccines
Nephrology
Neuroscience
Ophthalmology
Respiratory
Rheumatology
Rare Diseases
Cell & Gene Therapy
Radiation Therapy & Radiopharmaceuticals
Women’s Health
Pediatrics
Medical Devices & Diagnostics
This broad therapeutic expertise enables Medpace to provide specialized support across diverse clinical development programs. Medpace Corporate
Medpace has demonstrated consistent growth in revenue and earnings. In Q2 2025, the company reported:
Revenue: $603.3 million (14% year-over-year increase)
Earnings Per Share (EPS): $3.10
The company also raised its full-year 2025 guidance, forecasting earnings per share between $13.76 and $14.53. Barron's
Despite strong financial performance, Medpace faced challenges in Q1 2025:
Bookings: $500 million, missing expectations for the fifth consecutive quarter
Book-to-Bill Ratio: 0.9, below the expected 1.03
The decline in bookings was attributed to factors such as elevated cancellations and lower growth bookings, leading to investor uncertainty. Investors
Ticker Symbol: MEDP
Exchange: NASDAQ
Current Price: $490.64 (as of the latest trading session)